Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Operating Leases (2019 - 2025)

Historic Operating Leases for CorMedix (CRMD) over the last 7 years, with Q3 2025 value amounting to $2.4 million.

  • CorMedix's Operating Leases rose 33367.68% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 33367.68%. This contributed to the annual value of $349091.0 for FY2024, which is N/A changed from last year.
  • CorMedix's Operating Leases amounted to $2.4 million in Q3 2025, which was up 33367.68% from $435000.0 recorded in Q2 2025.
  • In the past 5 years, CorMedix's Operating Leases registered a high of $2.4 million during Q3 2025, and its lowest value of $349091.0 during Q4 2024.
  • Its 5-year average for Operating Leases is $780056.4, with a median of $702973.5 in 2022.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 4720503.56% in 2021, then crashed by 3121.27% in 2023.
  • Quarter analysis of 5 years shows CorMedix's Operating Leases stood at $802433.0 in 2021, then grew by 0.07% to $803000.0 in 2022, then fell by 12.45% to $703000.0 in 2023, then plummeted by 50.34% to $349091.0 in 2024, then soared by 590.72% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $435000.0 for Q2 2025, and $476000.0 during Q1 2025.